Alpha 2.0
Login Register
» Authors » Maria Garriga

Maria Garriga

Explore the profile of Maria Garriga including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 156
Followers 0
Related Specialties
Pulmonary Medicine
Pediatrics
General Medicine
Top 10 Co-Authors
Joaquim Calvo-Lerma
Carmen Ribes-Koninckx
Etna Masip
Kris De Boeck
Carla Colombo
Mieke Boon
Anna Bulfamante
Ana Andres
Jessie Hulst
Ine Claes
Published In
J Cyst Fibros
Nutrients
J Craniofac Surg
PLoS One
Pediatr Res
Affiliations
Soon will be listed here.
Recent Articles
11.
A body weight loss- and health-promoting gut microbiota is established after bariatric surgery in individuals with severe obesity
Sanchez-Carrillo S, Ciordia S, Rojo D, Zubeldia-Varela E, Mendez-Garcia C, Martinez-Martinez M, et al.
J Pharm Biomed Anal . 2020 Nov; 193:113747. PMID: 33217711
Obesity has reached an epidemic level worldwide, and bariatric surgery (BS) has been proven to be the most efficient therapy to reduce severe obesity-related comorbidities. Given that the gut microbiota...
12.
Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial
Lopez-Neyra A, Suarez L, Munoz M, de Blas A, Ruiz de Valbuena M, Garriga M, et al.
Prostaglandins Leukot Essent Fatty Acids . 2020 Oct; 162:102186. PMID: 33038833
Background: Cystic fibrosis (CF) patients have an alteration in fatty acid (FA) metabolism, associated with increased omega-6 and low omega-3 FA. Previous studies on supplementation with omega-3 FA in CF...
13.
Association between faecal pH and fat absorption in children with cystic fibrosis on a controlled diet and enzyme supplements dose
Calvo-Lerma J, Roca M, Boon M, Colombo C, De Koning B, Fornes-Ferrer V, et al.
Pediatr Res . 2020 Apr; 89(1):205-210. PMID: 32247283
Background: Despite treatment with pancreatic enzyme replacement therapy (PERT), patients with cystic fibrosis (CF) can still suffer from fat malabsorption. A cause could be low intestinal pH disabling PERT. The...
14.
The Intracellular Intensity of CD3 on Aberrant Intraepithelial Lymphocytes Is a Prognostic Factor of the Progression to Overt Lymphoma in Refractory Celiac Disease Type II (Pre-Enteropathy-Associated T Cell Lymphoma)
Garcia-Hoz C, Crespo L, Lopez N, De Andres A, Rios Leon R, Santon A, et al.
Dig Dis . 2020 Feb; 38(6):490-499. PMID: 32015237
Background: Refractory celiac disease type II (RCD-II) is a very rare yet severe complication of celiac disease (CD) with a 50% rate of progression to Enteropathy-associated T-cell lymphoma (EATL). Timely...
15.
Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents
Boon M, Claes I, Havermans T, Fornes-Ferrer V, Calvo-Lerma J, Asseiceira I, et al.
PLoS One . 2019 Dec; 14(12):e0225004. PMID: 31860639
Background: Most patients with cystic fibrosis (CF) suffer from pancreatic insufficiency, leading to fat malabsorption, malnutrition and abdominal discomfort. Until recently, no specific tool was available for assessing gastro-intestinal related...
16.
The Relative Contribution of Food Groups to Macronutrient Intake in Children with Cystic Fibrosis: A European Multicenter Assessment
Calvo-Lerma J, Hulst J, Boon M, Martins T, Ruperto M, Colombo C, et al.
J Acad Nutr Diet . 2019 Mar; 119(8):1305-1319. PMID: 30862484
Background: Optimal nutrition for children with cystic fibrosis (CF) improves prognosis and survival, but an increased caloric intake recommendation for this population raises concerns about the nutrient profile of their...
17.
Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis
Calvo-Lerma J, Hulst J, Boon M, Colombo C, Masip E, Ruperto M, et al.
PLoS One . 2019 Mar; 14(3):e0213216. PMID: 30861039
Background: A method to adjust Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis is not currently available. Objectives: To assess the in vivo efficacy of a method to adjust the dose...
18.
Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines
Calvo-Lerma J, Hulst J, Asseiceira I, Claes I, Garriga M, Colombo C, et al.
J Cyst Fibros . 2017 Mar; 16(4):510-518. PMID: 28320633
Background: The New European guidelines have established the most updated recommendations on nutrition and pancreatic enzyme replacement therapy (PERT) in CF. In the context of MyCyFAPP project - a European...
19.
Validity of a Spanish Version of the Leicester Cough Questionnaire in Children With Cystic Fibrosis
Del Corral T, Percegona J, Lopez N, Valiente A, Garriga M, Seborga M, et al.
Arch Bronconeumol . 2015 Jul; 52(2):63-9. PMID: 26163742
Background: Cystic fibrosis (CF) patients present chronic cough as one of the main symptoms, which has an important effect on quality of life and social relations. Our goal was to...
20.
Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study
Del Campo R, Garriga M, Perez-Aragon A, Guallarte P, Lamas A, Maiz L, et al.
J Cyst Fibros . 2014 Mar; 13(6):716-22. PMID: 24636808
Background: Although scientific knowledge about the benefits of probiotic use in cystis fibrosis (CF) is scarce, their expectative is promising. The aim of this work was to analyze the effect...